OncoZenge
Manufacturing · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Gustavslundsvägen 34, Bromma, Stockholm,...Phone Number
+46 760098499Website
www.oncozenge.seRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About OncoZenge
OncoZenge is a Swedish pharmaceutical company developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation treatment and chemotherapy for cancer.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OncoZenge your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on OncoZenge recently announced quarterly report
Funding: Get notified immidiatlly once OncoZenge has new funding data
Click to see if OncoZenge had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
OncoZenge, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if OncoZenge is spiking on competitors!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when OncoZenge launches new products
Check if OncoZenge has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at OncoZenge
Recommended Actions
Reach out to Masked Content who joined OncoZenge as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
OncoZenge is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
OncoZenge is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about OncoZenge.
OncoZenge financials insights
Gather financial insights about OncoZenge, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$3.1M
OncoZenge Tech Stack
A closer look at the technologies used by OncoZenge
See more technologies
OncoZenge News & Media
OncoZenge Receives Investment Capital From Yangtian Bio-Pharmaceutical - TradingView
OncoZenge ABOncoZenge AB (publ) ("OncoZenge" or "the Company") today announces receipt of the initial investment capital from Sichuan Yangtian Bio-Pharmaceutical Co., Ltd. (the ”Investor”).On January 27, 2025, OncoZenge announced that the Company had entered into an investment agreement which provi…OncoZenge AB intends to enter partnership with Pharmanovia for commercialization of BupiZenge™ in Europe, Middle East & North Africa
STOCKHOLM, SWEDEN – October 18, 2024 – OncoZenge AB (publ) (“OncoZenge” or the “Company”), announces the intention to partner with the global pharmaceutical leader Pharmanovia regarding exclusive rights to commercialization of BupiZenge™ in Europe, the Middle East, and Northern Africa (the “EMENA region”). The Company has signed a non-binding offer from Pharmanovia for a commercial partnership to introduce BupiZenge™ in Europe, the Middle East and Northern Africa. The parties will now enter a peOncoZenge participates in MASCC cancer care conference June 27-29
Stockholm, Sweden – June 4 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces its participation in the 2024 Multinational Association of Supportive Care in Cancer (MASCC) annual meeting taking place in Lille, France on June 27-29, 2024. The MASCC annual meeting is a premier gathering of healthcare professionals dedicated to improving the quality of life for cancer patients. Consistent with MASCC’sOncoZenge Appoints Anna Asplind as Phase 3 Program Manager
Stockholm, Sweden – April 26 2024 – OncoZenge AB (publ), a leading pharmaceutical company developing BupiZenge™, an innovative, non-opioid treatment for oral pain, today announces the appointment of Anna Asplind as Phase 3 Program Manager. As previously communicated the OncoZenge strategy and focus is planning for a pivotal phase 3-program towards European market authorization of BupiZenge™, together with a partner. The company is still evaluating the best partner options and plans but is please
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding OncoZenge
Sign Up For FreeTo access detailed company insights
OncoZenge is a Swedish pharmaceutical company developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation treatment and chemotherapy for cancer.... Read More
